Soft drug design: General principles and recent applications

Medicinal Research Reviews

Volumn 20, Issue 1, 2000, Pages 58-101

  Bodor, Nicholas ^a,b   Buchwald, Peter ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Ester hydrolysis; Loteprednol etabonate; Metabolism; Soft blockers; Soft drugs

Indexed keywords

2 (3 MERCAPTO 2 METHYLPROPIONYLOXY) 3 METHYLTHIOPROPIONIC ACID; 4 PHENYLCARBAMOYL 2,6 BIS(1 PYRROLIDINYLMETHYL)PHENOL; ALFENTANIL; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIINFECTIVE AGENT; ANTIPSORIASIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLOROBENZILATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESMOLOL; ETOMIDATE; FENOTEROL; FENTANYL; FLESTOLOL; ISOPRENALINE; LANDIOLOL; LOTEPREDNOL ETABONATE; METOPROLOL; PERHEXILINE; PROPRANOLOL; REMIFENTANIL; SALBUTAMOL; SUFENTANIL; TERBUTALINE; TIMOLOL;

DRUG CONFORMATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG HYDROLYSIS; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; REVIEW; STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; PHARMACEUTICAL PREPARATIONS;

EID: 0033966357     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X     Document Type: Review

References (208)

1. Bodor N. Novel approaches for the design of membrane transport properties of drugs. In: Roche EB, editor. Design of biopharmaceutical properties through prodrugs and analogs. Washington, D.C.: Acad Pharmaceut Sci; 1977. p 98-135.
2. Bodor N. Soft drugs: strategies for design of safer drugs. In: Buisman JAK, editor. Strategy in drug research. Proc 2nd IUPAC-IUPHAR Symp Res, Noordwijkerhout, The Netherlands. Amsterdam: Elsevier; 1982. p 137-164.
3. Bodor N. Designing safer drugs based on the soft drug approach. Trends Pharmacol Sci 1982;3:53-56.
4. Bodor N. Novel approaches to the design of safer drugs: Soft drugs and site-specific chemical delivery systems. Adv Drug Res 1984;13:255-331.
5. Bodor N. Soft drugs: principles and methods for the design of safe drugs. Med Res Rev 1984;3:449-469.
6. Bodor N. The soft drug approach. Chemtech 1984;14:28-38.
7. Bodor N. Soft drugs. In: Dulbecco R, editor. Encyclopedia of human biology. San Diego: Academic; 1991. Vol. 7. p 101-117.
8. Bodor N, Buchwald P. Drug targeting via retrometabolic approaches. Pharmacol Ther 1997;76:1-27.
9. Bodor N. Prodrugs versus soft drugs. In: Bundgaard H, editor. Design of prodrugs. Amsterdam: Elsevier; 1985. p 333-354.
10. Albert A. Chemical aspects of selective toxicity. Nature 1958;182:421-427.
11. Stella VJ. Prodrugs: an overview and definition. In: Higuchi T, Stella VJ, editors. Prodrugs as novel drug delivery systems. Washington, D.C.: Am Chem Soc; 1975. p 1-115.
12. Bundgaard H, editor. Design of prodrugs. Amsterdam: Elsevier Science; 1985.
13. Bodor N, Kaminski JJ. Prodrugs and site-specific chemical delivery systems. Annu Rep Med Chem 1987;22:303-313.
14. Balant LP, Doelker E. Metabolic considerations in prodrug design. In: Wolff ME, editor. Burger's medicinal chemistry and drug discovery. New York: Wiley Interscience; 1995. Vol. 1. p 949-982.
15. Wermuth CG, Gaignault JC, Marchandeau C. Designing prodrugs and bioprecursors I: Carrier prodrugs. In: Wermuth CG, editor. The practice of medicinal chemistry. London: Academic; 1996. p 671-696.
16. Stella VJ, editor. Themed issue. Low molecular weight prodrugs. Adv Drug Deliv Rev 1996;19:111-330.
17. Anderson BD. Prodrugs for improved CNS delivery. Adv Drug Deliv Rev 1996;19:171-202.
18. Lee HJ, Soliman MRI. Anti-inflammatory steroids without pituitary-adrenal suppression. Science 1982;215:989-991.
19. Heiman AS, Ko DH, Chen M, Lee HJ. New steroidal anti-inflammatory antedrugs. Steroids 1997;62:491-499.
20. Bodor N, Kaminski JJ, Selk S. Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials. J Med Chem 1980;23:469-474.
21. Bodor N, Kaminski JJ. Soft drugs. 2. Soft alkylating compounds as potential antitumor agents. J Med Chem 1980;23:566-569.
22. Bodor N, Woods R, Raper C, Kearney P, Kaminski J. Soft drugs. 3. A new class of anticholinergic agents. J Med Chem 1980;23:474-480.
23. Gillette JR. Effects of induction of cytochrome P-450 enzymes on the concentration of foreign compounds and their metabolites and on the toxicological effects of these compounds. Drug Metab Rev 1979;10: 59-87.
24. Picot A, Macherey AC. Chemical aspects of biotransformations leading to toxic metabolites. In: Wermuth CG, editor. The practice of medicinal chemistry. London: Academic; 1996. p 643-670.
25. Bodor N, Farag HH, Brewster ME. Site-specific, sustained release of drugs to the brain. Science 1981;214:1370-1372.
26. Bodor N. Targeting of drugs to the brain. Method Enzymol 1985;112:381-396.
27. Bodor N. Redox drug delivery systems for targeting drugs to the brain. Ann NY Acad Sci 1987;507:289-306.
28. Bodor N, Prokai L. Site-and stereospecific ocular drug delivery by sequential enzymatic bioactivation. Pharm Res 1990;7:723-725.
29. Bodor N, Brewster ME. Chemical delivery systems. In: Juliano RL, editor. Targeted drug delivery. Berlin: Springer-Verlag; 1991. Vol. 100. p 231-284.
30. Bodor N, Buchwald P. All in the mind. Chem Br 1998;34(1):36-40.
31. Bodor N, Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev 1999;36:229-254.
32. Bodor N. Drug targeting and retrometabolic drug design approaches. Adv Drug Deliv Rev 1994;14:157-166.
33. Bodor N. Retrometabolic approaches to drug targeting. In: Rapaka R, editor. Membranes and barriers: Targeted drug delivery. Rockville: NIDA; 1995. Vol. 154. p 1-27.
34. Mannering GJ. Hepatic cytochrome P-450-linked drug-metabolizing systems. In: Testa B, Jenner P, editors. Concepts in drug metabolism part B. New York: Marcel Dekker; 1981. p 53-166.
35. Leinweber FJ. Possible physiological roles of carboxylic ester hydrolases. Drug Metab Rev 1987;18:379-439.
36. Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 1998;38:257-288.
37. Augustinsson KB. Multiple forms of esterase in vertebrate blood plasma. Ann NY Acad Sci 1961;94:844-860.
38. Quon CY, Mai K, Patil G, Stampfli HF. Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab Dispos 1988;16:425-428.
39. Minagawa T, Kohno Y, Suwa T, Tsuji A. Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem Pharmacol 1995;49:1361-1365.
40. Chappell WR, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Adv Drug Res 1991;20:1-116.
41. Campbell DB. Extrapolation from animals to man. The integration of pharmacokinetics and pharmacodynamics. Ann NY Acad Sci 1996;801:116-135.
42. Quon CY, Stampfli HF. Biochemical properties of blood esmolol esterase. Drug Metab Dispos 1985;13: 420-424.
43. Feldman PL, James MK, Brackeen MF, Bilotta JM, Schuster SV, Lahey AP, Lutz MW, Johnson MR, Leighton HJ. Design, synthesis, and pharmacological evaluation of ultrashort-to long-acting opioid analgetics. J Med Chem 1991;34:2202-2208.
44. Stampfli HF, Quon CY. Polymorphic metabolism of flestolol and other ester containing compounds by a carboxylesterase in New Zealand white rabbit blood and cornea. Res Commun Mol Pathol Pharmacol 1995;88:87-97.
45. Kam ST, Matier WL, Mai KX, Barcelon-Yang C, Borgman RJ, O'Donnell JP, Stampfli HF, Sum CY, Anderson WG, Gorczynski RJ, Lee RJ. [(Arylcarbonyl)oxy]propanolamines. 1. Novel β-blockers with ultrashort duration of action. J Med Chem 1984;27:1007-1016.
46. Graffner-Nordberg M, Sjödin K, Tunek A, Hallberg A. Synthesis and enzymatic hydrolysis of esters, constituting simple models of soft drugs. Chem Pharm Bull 1998;46;591-601.
47. Godefroi EF, Janssen PAJ, van der Eycken CAM, van Heertum AHMT, Niemegeers CJE. DL-1-(1-Arylalkyl)imidazole-5-carboxylate esters. A novel type of hypnotic agents. J Med Chem 1965;8:220-223.
48. Lewi PJ, Heykants JJP, Janssen PAJ. Intravenous pharmacokinetic profile in rats of etomidate, a short-acting hypnotic drug. Arch Int Pharmacodyn Ther 1976;220:72-85.
49. Janssen PAJ, Niemegeers CJE, Schellekens KHL, Lenaerts FM. Etomidate, R-(+)-ethyl-1-(α-methylbenzyl)imidazole-5-carboxylate (R 16659), a potent, short-acting and relatively atoxic intravenous hypnotic agent in rats. Arzneim-Forsch 1971;21:1234-1243.
50. Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RPF, Sunder N, Weakly JN, Wastila WB, Eel-Sayad HA. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug. Anesthesiol 1988;68:723-732.
51. Korolkovas A. Essentials of medicinal chemistry. 2nd ed. New York: Wiley; 1988.
52. Nogrady T. Medicinal chemistry. A biochemical approach. 2nd ed. New York: Oxford Univ; 1988.
53. Bodor N. 1-Hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts. U. S. Patent, 3998815; 1976.
54. Calvani M, Critelli L, Gallo G, Giorgi F, Gramiccioli G, Santaniello M, Scafetta N, Tinti MO, De Angelis F. 1-Carnitine esters as "soft," broad-spectrum antimicrobial amphiphiles. J Med Chem 1998;41:2227-2233.
55. Ali-Melkillä T, Kanto J, Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 1993;37:633-642.
56. MacMillan FSK, Reller HH, Synder FH. The antiperspirant action of topically applied anticholinergics. J Invest Dermatol 1964;43:363-377.
57. Kumar GN, Bodor N. Soft anticholinergics. Curr Med Chem 1996;3:23-36.
58. Brouillette G, Kawamura M, Kumar GN, Bodor N. Soft drugs. 21. Design and evaluation of soft analogs of propantheline. J Pharm Sci 1996;85:619-623.
59. Hammer R, Amin K, Gunes ZE, Brouillette G, Bodor N. Novel soft anticholinergic agents. Drug Des Deliv 1988;2:207-219.
60. Bodor N, El-Koussi A, Hammer R. Soft drugs. 9. The ultra-short duration of the muscarinolytic activity of a new short-acting "soft" mydriatic agent. J Biopharm Sci 1990;1:215-223.
61. Hammer RH, Wu WM, Sastry JS, Bodor N. Short acting soft mydriatics. Curr Eye Res 1991;10:565-570.
62. Kumar GN, Hammer RH, Bodor N. Soft drugs. 16. Design, evaluation and transdermal penetration of novel soft anticholinergics based on methatropine. Bioorg Med Chem 1993;1:327-332.
63. Hammer RH, Gunes E, Kumar GN, Wu WM, Srinivasan V, Bodor N. Soft drugs. 14. Synthesis and anticholinergic activity of soft phenylsuccinic analogs of methatropine. Bioorg Med Chem 1993;1:183-187.
64. Juhász A, Huang F, Ji F, Buchwald P, Wu WM, Bodor N. Design and evaluation of new soft anticholinergic agents. Drug Develop Res 1998;43:117-127.
65. Kumar GN, Hammer RH, Bodor N. Soft drugs. 12. Design, synthesis, stability and evaluation of soft anticholinergics. Drug Des Discov 1993;10:11-21.
66. Kumar GN, Hammer RH, Bodor N. Soft drugs. 13. Design and evaluation of phenylsuccinic analogs of scopolamine as soft anticholinergics. Drug Des Discov 1993;10:1-9.
67. Raatikainen MJP, Napolitano CA, Druzgala P, Dennis DM. Electrophysiological effects of a novel, short-acting and potent ester derivative of amiodarone, ATI-2001, in guinea pig isolated heart. J Pharmacol Exp Ther 1996;277:1454-1463.
68. Vrobel TR, Miller PE, Mostow ND, Rakita L. A general overview of amiodarone toxicity: its prevention, detection, and management. Prog Cardiovasc Dis 1989;31:393-426.
69. Ogiso T, Iwaki M, Tanino T, Nagai T, Ueda Y, Muraoka O, Tanabe G. Pharmacokinetics of indomethacin ester prodrugs: Gastrointestinal and hepatic toxicity and the hydrolytic capacity of various tissues in rats. Biol Pharm Bull 1996;19:1178-1183.
70. Stout DM, Black LA, Barcelon-Yang C, Matier WL, Brown BS, Quon CY, Stampfli HF. Ester derivatives of 2,6-bis(1-pyrrolidinylmethyl)-4-benzamidophenol as short-acting antiarrhythmic agents. 1. J Med Chem 1989;32:1910-1913.
71. Chorvat RJ, Black LA, Ranade VV, Barcelon-Yang C, Stout DM, Brown BS, Stampfli HF, Quon CY. Mono- and bis(aminomethyl)phenylacetic acid esters as short-acting antiarrhythmic agents. 2. J Med Chem 1993;36:2494-2498.
72. Baxter AJG, Carr RD, Eyley SC, Fraser-Rae L, Hallam C, Harper ST, Hurved PA, King SJ, Meghani P. (R)-2-(3-Mercapto-2(S)-methyl-1-oxo-propoxy)-3-(methylthio)propanoic acid, the first ultra-short-acting angiotensin converting enzyme inhibitor. J Med Chem 1992;35:3718-3720.
73. Marciniak G, Decolin D, Leclerc G, Decker N, Schwartz J. Synthesis and pharmacological properties of "soft drug" derivatives related to perhexiline. J Med Chem 1988;31:2289-2296.
74. Decker N, Grima M, Velly J, Marciniak G, Leclerc G, Schwartz J. Soft drug derivatives related to perhexiline. Part I. In vitro studies. Arzneim-Forsch/Drug Res 1988;38:905-908.
75. Decker N, Grima M, Velly J, Marciniak G, Leclerc G, Schwartz J. Soft drug derivatives related to perhexiline. Part II. In vivo studies. Arzneim-Forsch/Drug Res 1988;38:1110-1114.
76. Naik A, Irwin WJ, Griffin RJ. The reduction of azidoprofen: A model for a soft anti-inflammatory drug for topical application. Int J Pharm 1993;89:51-63.
77. Naik A, Irwin WJ, Griffin RJ. The hydrolysis of azidoprofen esters: A model for a soft anti-inflammatory drug for topical application. Int J Pharm 1993;89:65-74.
78. Naik A, Irwin WJ, Griffin RJ. Percutaneous absorption of azidoprofen, a model for a soft anti-inflammatory drug for topical application, Int J Pharm 1993;90:129-140.
79. Gill HS, Freeman S, Irwin WJ, Wilson KA. Soft β-adrenergic agonists for the topical treatment of psoriasis. Eur J Med Chem 1996;31:847-859.
80. Gill HS, Irwin WJ, Freeman S. Synthesis and stability studies of soft-drugs as β-adrenoceptor agonists for the treatment of psoriasis. Abst Pap Am Chem Soc 1994;208, Part 1:245-MEDI.
81. Müller P, editor. DDT. The insecticide dichlorodiphenyltrichloroethane and its significance. Basel: Birkhauser Verlag; 1955; Vol. 1.
82. O'Brien RD. Insecticides. Action and metabolism. New York: Academic; 1967.
83. Gaines TB. Acute toxicity of pesticides. Toxicol Appl Pharmacol 1969;14:515-534.
84. Kashyap SK, Nigatn SK, Karnik AB, Gupta RC, Chatterjee SK. Carcinogenicity of DDT (dichlorodiphenyhrichloroethane) in pure inbred Swiss mice. Int J Cancer 1979;19:725-729.
85. IARC. IARC Monograph Ser 1983;30:73-101.
86. Borg KO, Carlsson E, Hoffmann KJ, Jönsson TE, Thorin H, Wallin B. Metabolism of metoprolol-(3H) in man, the dog and the rat. Acta Pharmacol Toxicol 1975;36 (Sup V): 125-135.
87. Regårdh CG, Johnsson G. Clinical pharmacokinetics of metoprolol. Clin Pharmacokin 1980;5:557-569
88. Benfield P, Clissold SP, Brogden RN. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs 1986;31:376-429.
89. Bodor N, Oshiro Y, Loftsson T, Katovich M, Caldwell W. Soft drugs. VI. The application of the inactive metabolite approach for design of soft β-blockers. Pharm Res 1984;3:120-125.
90. Bodor N, El-Koussi A, Kano M, Khalifa MM. Soft drugs. 7. β-Blockers for systemic and ophthalmic use. J Med Chem 1988;31:1651-1656.
91. Bodor N, El-Koussi A. Novel 'soft' β-blockers as potential safe antiglaucoma agents. Curr Eye Res 1988;7:369-374.
92. Polgar P, Bodor N. Cardiac electrophysiologic effects of adaprolol maleate, a new β-blocker, in closed chest dogs. Life Sci 1991;48:1519-1528.
93. Bodor N, El-Koussi A, Zuobi K, Kovacs P. Synthesis and pharmacological activity of adaprolol enantiomers: anew soft drug for treating glaucoma. J Ocul Pharmacol Ther 1996;12:115-122.
94. Sugrue MF. New approaches to antiglaucoma therapy. J Med Chem 1997;40:2793-2809.
95. Yang HS, Wu WM, Bodor N. Soft drugs. XX. Design, synthesis and evaluation of ultra-short acting beta-blockers. Pharm Res 1995;12:329-336.
96. Erhardt PW, Woo CM, Anderson WG, Gorczynski RJ. Ultra-short-acting β-adrenergic receptor blocking agents. 2. (Arlyoxy)propanolamines containing esters on the aryl function. J Med Chem 1982;25:1408-1412.
97. Erhardt PW. A prodrug and a soft drug. In: Erhardt PW, editor. Drug metabolism. Databases and high throughput testing during drug design and development. Oxford: Blackwell Science; 1999. p 62-69.
98. Tatsuno H, Goto K, Shigenobu K, Kasuya Y, Obase H, Yamada Y, Kudo S. Synthesis and adrenergic β-blocking activity of some 1,3-benzodioxole derivatives. J Med Chem 1977;20:394-397.
99. O'Donnell JP, Parekh S, Borgman RJ, Gorczynski RJ. Synthesis and pharmacology of potential β-blockers. J Pharm Sci 1979;68:1236-1238.
100. Erhardt PW, Woo CM, Gorczynski RJ, Anderson WG. Ultra-short-acting β-adrenergic receptor blocking agents. 1. (Arlyoxy)propanolamines containing esters in the nitrogen substituent. J Med Chem 1982; 25:1402-1407.
101. Erhardt PW, Woo CM, Matier WL, Gorczynski RJ, Anderson WG. Ultra-short-acting β-adrenergic receptor blocking agents. 3. Ethylenediamine derivatives of (arlyoxy)propanolamines having esters on the aryl function. J Med Chem 1983;26:1109-1112.
102. Benfield P, Sorkin EM. Esmolol. Apreliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1987;33:392-412.
103. Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, Sakaki K, Hachiya K, Ichioka Y, Kawamura M. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull 1992;40:1462-1469.
104. Muraki K, Nakagawa H, Nagano N, Henmi S, Kawasumi H, Nakanishi T, Imaizumi K, Tokuno T, Atsuki K, Imaizumi Y, Watanabe M. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle. J Pharmacol Exp Ther 1996;278:555-563.
105. Kitamura A, Sakamoto A, Inoue T, Ogawa R. Efficacy of an ultrashort-acting β-adrenoreceptor blocker (ONO-1101) in attenuating cardiovascular responses to endotracheal intubation. Eur J Clin Pharmacol 1997;51:467-471.
106. Lin YT, Wu BN, Wu JR, Lo YC, Chen LC, Chen IJ. Vasomolol: an ultra short-acting and vasorelaxant vanilloid type β1-adrenoreceptor antagonist. J Cardiovasc Pharmacol 1996;28:149-157.
107. Gabourel JD, Gosselin RE. The mechanism of atropine detoxification in mice and rats. Arch Int Pharmacodyn 1958;115:416-431.
108. Gosselin RE, Gabourel JD, Wills JH. The fate of atropine in man. Clin Pharmacol Ther 1960;1:597-603.
109. Kumar GN, Huang MJ, Hammer R, Bodor N. Soft Drugs. 17. Quantitative structure-activity relationships of soft anticholinergics based on methatropine and methscopolamine. J Pharm Sci 1994;83:117-118.
110. Bodor N, Buchwald P. Molecular size based approach to estimate partition properties for organic solutes. J Phys Chem B 1997;101:3404-3412.
111. Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 1985;107:3902-3909,
112. Waldeck B. β-Adrenoceptor agonists after terbutaline. Pharmacol Toxicol 1995;77 (Sup III):25-29.
113. 2-Agonists containing metabolically labile groups. I. The influence of ester groups in the nitrogen substituent. Eur J Med Chem 1985;20:51-55.
114. 2-Agonists containing metabolically labile groups. II. The influence of ester groups in the aryl system. Eur J Med Chem 1985;20:57-60.
115. Meuldermans W, Hendrickx J, Lauwers W, Hurkmans R, Swysen E, Thijssen J, Timmerman P, Woestenborghs R, Heykants J. Excretion and biotransformation of alfentanil and sufentanil in rats and dogs. Drug Metab Dispos 1987;15:905-913.
116. Colapret JA, Diamantidis G, Spencer HK, Spaulding TC, Rudo FG. Synthesis and pharmacological evaluation of 4,4-disubstituted piperidines. J Med Chem 1989;32:968-974.
117. James MK, Feldman PL, Schuster SV, Bilotta JM, Brackeen MF, Leighton HJ. Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues. J Pharmacol Exp Ther 1991;259:712-718.
118. Egan TD, Lemmens HJM, Fiset P, Hermann DJ, Muir KT, Stanski DR, Shafer SL. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiol 1993;79:881-892.
119. Westmoreland CL, Hoke JF, Sebel PS, Hug CC, Muir KT. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiol 1993;79:893-903.
120. D'Amour FE, Smith DL. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941;72:74-79.
121. Haidar SH, Moreton JE, Liang Z, Hoke JF, Muir KT, Eddington ND. Evaluating a possible pharmacokinetic interaction between remifentanil and esmolol in the rat. J Pharm Sci 1997;86:1278-1282.
122. Bodor N. Soft steroids having antiinflammatory activity. Belgian Patent, BE889,563 (Cl. CO7J); 1981.
123. Bodor N, Varga M. Effect of a novel soft steroid on the wound healing of rabbit cornea. Exp Eye Res 1990;50:183-187.
124. Druzgala P, Hochhaus G, Bodor N. Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem 1991;38:149-154.
125. Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991;10:933-937.
126. Alberth M, Wu WM, Winwood D, Bodor N. Lipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory corticosteroid. J Biopharm Sci 1991;2:115-125.
127. Bodor NS, Kiss-Buris ST, Buris L. Novel soft steroids: effects on cell growth in vitro and on wound healing in the mouse. Steroids 1991;56:434-439.
128. Bodor N, Bodor N, Wu WM. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Curr Eye Res 1992;11:525-530.
129. Bodor N, Loftsson T, Wu WM. Metabolism, distribution, and transdermal permeability of a soft corticosteroid, loteprednol etabonate. Pharm Res 1992;9:1275-1278.
130. Hochhaus G, Chen LS, Ratka A, Druzgala P, Howes J, Bodor N, Derendorf H. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci 1992;81:1210-1215.
131. Loftsson T, Bodor N. The pharmacokinetics and transdermal delivery of loteprednol etabonate and related soft steroids. Adv Drug Deliv Rev 1994;14:293-299.
132. Bodor N, Murakami T, Wu WM. Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats for safer treatment of gastrointestinal inflammation. Pharm Res 1995;12:869-874.
133. Bodor N, Wu WM, Murakami T, Engel S. Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Pharm Res 1995;12:875-879.
134. Reddy IK, Khan MA, Wu WM, Bodor NS. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. J Ocul Pharmacol Ther 1996;12:159-167.
135. Buris LF, Bodor N, Buris L. Loteprednol etabonate, a new soft steroid is effective in a rabbit acute experimental model for arthritis. Pharmazie 1999;54:58-61.
136. Little RJ, Bodor N, Loftsson T. Soft drugs based on hydrocortisone: The inactive metabolite approach and its application to steroidal antiinflammatory agents. Pharm Res 1999;16:961-967.
137. Bartlett JD, Howes JF, Ghormley NR, Amos JF, Laibovitz R, Horwitz B. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993;12:313-321.
138. Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993;9:157-165.
139. Howes JF, Baru H, Vered M, Neumann R. Loteprednol etabonate: comparison with other steroids in two models of intraocular inflammation. J Ocul Pharmacol 1994;10:289-293.
140. Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 1997;23:31-36.
141. Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Am J Ophthalmol 1997;123:455-464.
142. Dell SJ, Shulman DG, Lowry GM, Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Am J Ophthalmol 1997;123:791-797.
143. Howes J, Novack GD. Failure to detect systemic levels and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration. J Ocul Pharmacol Th 1998;14:153-158.
144. Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 1998;102:251-255.
145. Shulman DG, Lothringer HL, Rubin JM. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmol 1999; 106:362-369.
146. Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 1998;7:266-269.
147. Beehler C, Bodner B, Bowman B, Cooke D, Crabb JL, DeBarge LR, Donnenfeld E, Estopinal M, Fox K, Kastl P, Olander K, Sharpe E, Shofner R, Stahl J, Stevenson D, Stewart W, Walters T, Gill S, Howes J, Lawson C, Smerick M, Zaccardelli D, Fazio R, Novack GD, Crockett RS, Hart K. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmol 1998;105:1780-1786.
148. Stewart R, Horwitz B, Howes J. A double-masked, placebo controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. J Cataract Refr Surg 1998;24:1480-1489.
149. Abelson M, Howes G, George M. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate. J Ocul Pharmacol Ther 1998;14:533-542.
150. Noble S, Goa KL. Loteprednol etabonate. Clinical potential in the management of ocular inflammation. BioDrugs 1998;10:329-339.
151. Caldwell D, Cohen GR, Davis J, DeBarge LR, Foley J, Foster CS, Fox K, Friedlaender M, John G, Kaufman A, Nozik R, Olander K, Ostrov C, Raizman M, Rosenbaum J, Sall K, Sheppard J, Stewart D, Stewart W, Tauber J, Trocme S, Zimmerman P, Howes J, Coultas S, Crockett RS, Novack GD, Strahlman ER, Neumann R. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 1999;127:537-544.
152. Raizman M. Corticosteroid therapy of eye disease: Fifty years later. Arch Ophthalmol 1996;114:1000-1001.
153. Dickerson JE Jr, Dotzel E, Clark AF Steroid-induced cataract: New perspectives from in vitro and lens culture studies. Exp Eye Res 1997;65:507-516.
154. Heyns K, Koch W. Über die Bildung eines Aminozuckers aus d-Fruktose und Ammoniak. Z Naturforsch B 1952;7B:486-488.
155. Bucala R, Fishman J, Cerami A. Formation of covalent adducts between Cortisol and 16α-hydroxyestrone and protein: Possible role in the pathogenesis of Cortisol toxicity and systemic lupus erythematosus. Proc Natl Acad Sci USA 1982;79:3320-3324.
156. Manabe S, Bucala R, Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest 1984;74:1803-1810.
157. Bucala R, Gallati M, Manabe S, Collier E, Cerami A. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res 1985;40:853-863.
158. Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986;31:102-110.
159. Monder C, Bradlow HL. Cortoic acids: explorations at the frontier of corticosteroid metabolism. Recent Prog Horm Res 1980;36:345-400.
160. Bodor N. The application of soft drug approaches to the design of safer corticosteroids. In: Christophers E, Kligman AM, Schöpf E, Stoughton RB, editors. Topical corticosteroid therapy: A novel approach to safer drugs. New York: Raven; 1988. p 13-25.
161. Bodor N. Design of novel soft corticosteroids. In: Korting H, editor. Topical glucocorticoids with increased benefit-risk ratio. Basel: Karger; 1993. Vol. 21. p 11-19.
162. Druzgala P, Bodor N. Regioselective O-alkylation of cortienic acid and synthesis of a new class of glucocorticoids containing a 17α-alkoxy, a 17α-(1′-alkoxyethyloxy), a 17α-alkoxymethyloxy, or a 17α-methylthiomethyloxy function. Steroids 1991;56:490-494.
163. Bodor N. Designing safer ophthalmic drugs. In: van der Goot H, Domany G, Pallos L, Timmerman H, editors. Trends in medicinal chemistry '88. Proc Xth Int Symp Med Chem. Amsterdam: Elsevier; 1989. p 145-164.
164. Gerhards E, Nieuweboer B, Schulz G, Gibian H. Berger D, Hecker W. Stoffwechsel von 6α-Fluor-16α-methyl-pregna-1,4-diene-11β,21-diol-3,20-dion (Fluocortolon) beim Menschen. Acta Endocr 1971; 68:98-126.
165. Laurent H, Gerhards E, Wiechert R. New biologically active pregnan-21-oic acid esters. J Steroid Biochem 1975;6:185-192.
166. Kapp JF, Koch H, Töpert M, Kessler HJ, Gerhards E. Unterschungen zur Pharmakologie von 6α-Fluor-11β-hydroxy-16α-methyl-3,20-dioxo-1,4-pregnadiene-21- säure- butylester (Fluocortin-butylester). Arzneim-Forsch 1977;27:2191-2202.
167. Kapp JF, Gliwitzki B, Josefiuk P, Weishaupt W. Dermale und systemische Nebenwirkungen von Fluocortin-butylester (FCB). Arzneim-Forsch 1977;27:2206-2213.
168. Reckers R. Klinische Prüfungen von Fluocortin-butylester im doppelblinden Halbseitenvergleich gegenüber Fluocortolon und Hydrocortisonacetat. Arzneim-Forsch 1977;27:2240-2244.
169. Taraporewala IB, Kim HP, Heiman AS, Lee HJ. A novel class of local antiinflammatory steroids. 1st communication: Analogues of methyl 11β, 17α,21-trihydroxy-3,20-dioxo-pregna-1,4-diene-16α-carboxylate. Arzneim-Forsch 1989;39:21-25.
170. Heiman AS, Kim HP, Taraporewala IB, Lee HJ. A novel class of local antiinflammatory steroids. 2nd communication: Pharmacological studies of methyl 11β,17α,21-trihydroxy-3,20-dioxo-pregna-1,4-diene-16α- carboxylate and methyl 11β,21-dihydroxy-3,20-dioxo-pregna-1,4-diene-16α-carboxylate. Arzneim-Forsch 1989;39:262-267.
171. McLean HM, Khalil MA, Heiman AS, Lee HJ. Novel fluorinated antiinflammatory steroid with reduced side effects: methyl 9α-fluoroprednisolone-16-carboxylate. J Pharm Sci 1994;83:476-479.
172. Heiman AS, Hong D, Lee HJ. Receptor binding affinity and antiproliferative activity of new antiinflammatory antedrugs: 6-methoxycarbonyl prednisolone and its derivalives. Steroids 1994;59:324-329.
173. Kwon T, Heiman AS, Oriaku ET, Yoon K, Lee HJ. New steroidal antiinflammatory antedrugs: Steroidal [16α,17α-d]-3′-carbethoxyisoxazolines. J Med Chem 1995;38:1048-1051.
174. Yoon KJ, Khalil MA, Kwon T, Choi SJ, Lee HJ. Steroidal anti-inflammatory antedrugs: synthesis and pharmacological evaluation of 16α-alkoxycarbonyl-17-deoxyprednisolone derivatives. Steroids 1995; 60:445-451 (515-521).
175. Khalil MA, Maponya MK, Ko DH, You Z, Oriaku ET, Lee HJ. New anti-inflammatory steroids: [16α, 17α-d] isoxazoline derivatives of prednisolone and 9α-fluoroprednisolone. Med Chem Res 1996;6:52-60.
176. Ko DH, Maponya MF, Khalil MA, Oriaku ET, You Z, Lee HJ. New anti-inflammatory steroids: [16α, 17α-d]-3′-hydroxy-iminoformyl isoxazoline derivatives of prednisolone and 9α-fluoroprednisolone. Med Chem Res 1997;7:313-324.
177. Lee HJ, Ko DH. Antedrug: a novel approach to the discovery of safer anti-inflammatory steroids. Soc Biomed Res Symp 1997;7:33-40.
178. Kimura T, Yamaguchi T, Usuki K, Kurosaki Y, Nakayama T, Fujiwara Y, Matsuda Y, Unno K, Suzuki T. Colonie mucosa-specific "pro-antedrugs" for oral treatment of ulcerative colitis: design, synthesis and fate of methyl 20-glucopyranosyloxyprednisolonates. J Control Release 1994;30:125-135.
179. Milioni C, Jung L, Koch B. Synthesis of new local anti-inflammatory thiosteroids based on antedrug concept. Eur J Med Chem 1991;26:947-951.
180. Ong JTH, Poulsen BJ, Akers WA, Scholtz JR, Genter FC, Kertesz DJ. Intrinsic potencies of novel thiol ester corticosteroids RS-85095 and RS-21314 as compared with clobetasol 17-propionate and fluocinonide. Arch Dermatol 1989;125:1662-1665.
181. Rohatagi S, Bye A, Falcoz C, Mackie AE, Meibohm B, Möllmann H, Derendorf H. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 1996; 36:938-941.
182. Thorsson L, Dahlström K, Edsbäcker S, Källén A, Paulson J, Wirén JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997;43:155-161.
183. Hamilton TC, Chapman V. Intrinsic sympathomimetic activity of β-adrenoceptor blocking drugs at cardiac and vascular β-adrenoceptors. Life Sci 1978;23:813-820.
184. Machin PJ, Hurst DN, Osbond JM. β-Adrenoceptor activity of the stereoisomers of the bufuralol alcohol and ketone metabolites. J Med Chem 1985;28:1648-1651.
185. Francis RJ, East PB, McLaren SJ, Larman J. Determination of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection. Biomed Mass Spectrom 1976;3:281-285.
186. Bodor N, Sloan KB. Soft drugs. V. Thiazolidine-type derivatives of progesterone and testosterone. J Pharm Sci 1982;71:514-520.
187. Schubert WM, Motoyama Y. An example of SN1 cleavage of a sulfide. J Am Chem Soc 1965;87:5507-5508.
188. Bodor N, Sloan KB, Little RJ, Selk SH, Caldwell L. Soft drugs. 4. 3-Spirothiazolidines of hydrocortisone and its derivatives. Int J Pharm 1982;10:307-321.
189. Bodor N, Gabanyi Z, Wong CK. A new method for the estimation of partition coefficient. J Am Chem Soc 1989;111:3783-3786.
190. Bodor N, Harget A, Huang MJ. Neural network studies. I. Estimation of the aqueous solubility of organic compounds. J Am Chem Soc 1991;113:9480-9483.
191. Bodor N, Huang MJ. An extended version of a novel method for the estimation of partition coefficients. J Pharm Sci 1992;81:272-281.
192. Bodor N, Huang MJ. A new method for the estimation of the aqueous
193. Buchwald P, Bodor N. Octanol-water partition of nonzwitterionic peptides: Predictive power of a molecular size-based model. Proteins 1998;30:86-99.
194. Buchwald P, Bodor N. Molecular size-based model to describe simple organic liquids. J Phys Chem B 1998;102:5715-5726.
195. Buchwald P, Bodor N. Octanol-water partition: Searching for predictive models. Curr Med Chem 1998;5:353-380.
196. Bodor N, Huang MJ. Computer-aided design of new drugs based on retrometabolic concepts. In: Reynolds CH, Holloway MK, Cox HK, editors. Computer-aided molecular design. Applications in agrochemicals, materials, and pharmaceuticals. Washington, DC: Am Chem Soc; 1994. p 98-113.
197. Bodor N, Huang MJ. Computational approaches to the design of safer drugs and their molecular properties. In: Leszczynski J, editor. Computational chemistry: Reviews of current trends. Singapore: World Scientific; 1996. Vol. 1 p 219-266.
198. Bodor N. Design of biologically safer chemicals. Chemtech 1995;25:22-32.
199. Bodor N, Buchwald P, Huang MJ. Computer assisted design of new drugs based on retrometabolic concepts. SAR QSAR Environ Res 1998;8:41-92.
200. Bodor N, Buchwald P. Soft drugs: designing safer drugs by simplifying drug metabolism. In: Erhardt PW, editor. Drug metabolism. Databases and high-throughput testing during drug design and development. Oxford: Blackwell Science; 1999. p 223-235.
201. Bodor N, Buchwald P, Huang MJ. The role of computational techniques in relrometabolic drug design strategies. In: Leszczynski J, editor. Computational molecular biology. Amsterdam: Elsevier; 1999. p 569-618.
202. Karelson M, Lobanov VS, Katritzky AR. Quantum-chemical descriptors in QSAR/QSPR studies. Chem Rev 1996;96:1027-1043.
203. Mechoulam R, Lander N, Breuer A, Zahalka J. Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocanabinoid derivative. Tetrahedron: Assymmetry 1990;1:315-318.
204. Mechoulam R, Devane WA, Breuer A, Zahalka J. A random walk through a cannabis field. Pharmacol Biochem Behav 1991;40:461-464.
205. Feigenbaum JJ, Bergman F, Richmond SA, Mechoulam R, Nadler V, Kloog J, Sokolovsky M. Nonpsychotropic cannabinoid acts as a functional N-melhyl-D-aspartate receptor blocker. Proc Nat Acad Sci USA 1989;86:9584-9587.
206. Razdan RK, Howes JF. Drugs related to tetrahydrocannabinol. Med Res Rev 1983;3:119-146.
207. Hollister LE. Health-aspects of cannabis. Pharmacol Rev 1986;38:1-20.
208. Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol Rev 1986;38:75-146.